Literature DB >> 2568519

Randomised trial of fish oil for prevention of restenosis after coronary angioplasty.

G J Reis1, T M Boucher, M E Sipperly, D I Silverman, C H McCabe, D S Baim, F M Sacks, W Grossman, R C Pasternak.   

Abstract

To examine the potential role of fish oil supplementation in the prevention of restenosis after coronary angioplasty (PTCA), a randomised double-blind trial was conducted in 204 patients. The treatment group received 6 g/day of n-3 fatty acids, beginning 5.4 (SD 3.2) days before PTCA, and continuing for 6 months; the control group received olive oil placebo. Compliance was assessed by pill count and plasma levels of eicosapentaenoic acid (EPA). Restenosis was identified by symptoms and exercise testing and confirmed by angiography. PTCA was successful in 186 patients (93%). The incidence of angiographic restenosis was 34% in the fish oil group and 23% in the control group (relative risk 1.7, 95% CI 0.9-3.4). The lack of benefit of fish oil was not influenced by length of pretreatment, compliance with study medication, or the concentrations of plasma EPA achieved.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2568519     DOI: 10.1016/s0140-6736(89)90370-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  27 in total

1.  Restenosis after coronary angioplasty: a proposal of new comparative approaches based on quantitative angiography.

Authors:  P W Serruys; D P Foley; P J de Feyter
Journal:  Br Heart J       Date:  1992-10

2.  Lipids, atherosclerosis, and restenosis after percutaneous transluminal coronary angioplasty.

Authors:  J J Ferguson; J T Willerson
Journal:  Tex Heart Inst J       Date:  1992

Review 3.  Is there a rational use for n-3 fatty acids (fish oils) in clinical medicine?

Authors:  A Nordøy
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 4.  Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? (Part II).

Authors:  J P Herrman; W R Hermans; J Vos; P W Serruys
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

Review 5.  Risk factors, interventions and therapeutic agents in the prevention of atherosclerosis-related ischaemic diseases.

Authors:  M Verstraete
Journal:  Drugs       Date:  1991       Impact factor: 9.546

6.  Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: results of SHIPS (SHIga Pravastatin Study).

Authors:  Y Nakamura; O Yamaoka; K Uchida; N Morigami; Y Sugimoto; T Fujita; T Inoue; T Fuchi; M Hachisuka; H Ueshima; H Shimakawa; M Kinoshita
Journal:  Cardiovasc Drugs Ther       Date:  1996-09       Impact factor: 3.727

7.  The ω-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation trial--rationale and design.

Authors:  Dariush Mozaffarian; Roberto Marchioli; Tim Gardner; Paolo Ferrazzi; Patrick O'Gara; Roberto Latini; Peter Libby; Federico Lombardi; Alejandro Macchia; Richard Page; Massimo Santini; Luigi Tavazzi; Gianni Tognoni
Journal:  Am Heart J       Date:  2011-06-12       Impact factor: 4.749

Review 8.  Effects of omega-3 fatty acids on cytokines and adhesion molecules.

Authors:  Raffaele De Caterina; Rosalinda Madonna; Marika Massaro
Journal:  Curr Atheroscler Rep       Date:  2004-11       Impact factor: 5.113

Review 9.  Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials.

Authors:  Kristian B Filion; Fouad El Khoury; Michael Bielinski; Ian Schiller; Nandini Dendukuri; James M Brophy
Journal:  BMC Cardiovasc Disord       Date:  2010-06-03       Impact factor: 2.298

Review 10.  Pharmacological approaches to the prevention of restenosis after coronary angioplasty.

Authors:  M Hamon; E Lécluse; J P Monassier; G Grollier; J C Potier
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.